NAICS 325413 Quarterly Industry Report
In-Vitro Diagnostic Substance Manufacturing
Comprehensive industry research for valuation professionals, business owners, buyers, and lenders
NAICS Code: 325413Sector: 32Updated: Q1 2026
About This Report
This Fair Market Value industry report for NAICS 325413 provides business owners, acquirers, and financial advisors with data-driven valuation insights for the in-vitro diagnostic substance manufacturing sector, drawing on data from the U.S. Census Bureau[5] and FDA[9] medical device registration statistics. Additional data is drawn from Bureau of Labor Statistics[10].. The report aggregates transaction multiples, financial benchmarks, and market trends specific to NAICS 325413 establishments, supporting buy-sell agreements, succession planning, SBA-financed acquisitions, and litigation support engagements.
Industry Snapshot
Key metrics for the in-vitro diagnostic substance manufacturing industry.
Industry Definition & Overview
In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) encompasses establishments primarily engaged in manufacturing in-vitro diagnostic substances, including chemical, biological, and radioactive substances used for diagnostic tests performed in test tubes, petri dishes, analyzers, and other laboratory diagnostic devices. Products include blood glucose test strips, pregnancy test reagents, clinical chemistry reagents, immunoassay kits, molecular diagnostic reagents, and point-of-care testing consumables. According to the U.S. Census Bureau[5], approximately 194 companies operate across 260 establishments, employing nearly 37,700 workers with annual payroll exceeding $3.9 billion, reflecting the highly skilled workforce required for diagnostic reagent manufacturing.
The industry generated over $8 billion in exports according to the International Trade Administration[6], making the U.S. a net exporter of diagnostic substances to global healthcare markets. Product development spans clinical chemistry, hematology, microbiology, immunology, and molecular diagnostic platforms, with manufacturers producing reagents calibrated to specific analyzer systems in closed or open platform configurations. The Bureau of Labor Statistics[7] identifies production roles including fermentation technicians producing monoclonal antibodies for immunoassays, formulation scientists developing reagent chemistries, quality control analysts performing lot-release testing, clean room manufacturing operators handling biological materials, and regulatory affairs specialists managing FDA 510(k) and premarket approval submissions.
Per the SBA Office of Advocacy[8], the industry includes large multinational diagnostic companies operating integrated instrument-and-reagent platforms alongside smaller specialty manufacturers producing niche diagnostic reagents, point-of-care test kits, and laboratory-developed test components. The razor-and-blade business model, where instrument placement drives recurring reagent revenue, creates highly predictable revenue streams that support premium business valuations.
What's Included in This Industry
- Valuation multiples benchmarked to in-vitro diagnostic substance manufacturing operations
- Revenue and EBITDA trends for domestic IVD reagent and test kit production
- SBA lending data and financing terms for NAICS 325413 businesses
- Comparable transaction data from recent diagnostic company acquisitions
- Industry risk factors including FDA regulatory changes, reimbursement pressure, and technology shifts
- Workforce composition and labor cost benchmarks for IVD manufacturing operations
- Regional market analysis covering diagnostic manufacturing clusters
- Capital expenditure benchmarks for clean room production and reagent filling equipment
- Growth projections tied to molecular diagnostics and point-of-care testing expansion
- Owner compensation and discretionary earnings benchmarks
NAICS Classification Hierarchy
| Level | Description | Code |
|---|---|---|
| Subsector | Chemical Manufacturing | 325 |
| Industry Group | Pharmaceutical and Medicine Manufacturing | 3254 |
| NAICS Industry | Pharmaceutical and Medicine Manufacturing | 32541 |
| National Industry | In-Vitro Diagnostic Substance Manufacturing | 325413 |
Related NAICS Codes
| Code | Description | Relationship |
|---|---|---|
| 325411 | Medicinal and Botanical Manufacturing | Medicinal and botanical manufacturers producing pharmaceutical-grade biological and chemical raw materials consumed in diagnostic reagent formulation manufacturing processes |
| 325414 | Biological Product (except Diagnostic) Manufacturing | Biological product manufacturers sharing monoclonal antibody production capabilities and cGMP biological manufacturing infrastructure with diagnostic substance producers |
| 339113 | Surgical Appliance and Supplies Manufacturing | Surgical and medical instrument manufacturers producing diagnostic analyzer instruments that consume reagent test kits manufactured by in-vitro diagnostic substance producers |
| 339112 | Surgical and Medical Instrument Manufacturing | Surgical and medical instrument manufacturers producing specimen collection and sample preparation devices used alongside diagnostic reagent products in clinical testing |
| 621511 | Medical Laboratories | Medical laboratories consuming diagnostic reagents and test kits as primary operational inputs for performing clinical diagnostic testing on patient specimens |
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | Biotechnology research organizations developing novel diagnostic biomarkers and assay technologies that generate demand for new diagnostic reagent manufacturing |
Geographic Concentration
Top states by share of national establishments.
| # | State | % Est. | Total Est. |
|---|---|---|---|
| 1 | California | 29.3% | 71 |
| 2 | Texas | 5.4% | 13 |
| 3 | Massachusetts | 4.1% | 10 |
| 4 | New Jersey | 4.1% | 10 |
| 5 | New York | 4.1% | 10 |
| 6 | Georgia | 3.7% | 9 |
| 7 | Florida | 3.7% | 9 |
| 8 | Wisconsin | 3.3% | 8 |
| 9 | Minnesota | 3.3% | 8 |
| 10 | Maryland | 3.3% | 8 |
% Of Establishments
0%
29%
Source: County Business Patterns, U.S. Census Bureau[3]
SBA Lending Summary
16
Total SBA Loans
$7.2M
Total Loan Volume
$450K
Average Loan Size
10 yrs
Average Loan Term
9.50%
Average Interest Rate
160
Jobs Supported
Source: SBA 7(a) Program Data, U.S. Small Business Administration — FY 2025[4]
Key Insight: In-vitro diagnostic manufacturers evaluating SBA financing must consider qualification under the SBA size standards[11] for NAICS 325413, which set the threshold at 1,250 employees for small business classification. The SBA 7(a) loan program[12] supports smaller diagnostic reagent producers and specialty test kit manufacturers acquiring operations or financing working capital for biological raw material procurement, while the CDC/504 loan program[13] provides long-term fixed-rate financing for clean room buildouts, reagent filling lines, cold storage facilities, and quality testing laboratory equipment. Lenders evaluate FDA product clearance portfolios, reagent rental contract backlogs, and customer concentration among reference laboratories when structuring IVD manufacturing loans.
Top SBA Lenders
| # | Lender | Loans | Volume | Avg Loan |
|---|---|---|---|---|
| 1 | KeyBank National Association | 16 | $7.2M | $450K |
Frequently Asked Questions
Common questions about this industry.
What is the typical valuation multiple for an IVD manufacturer?
In-vitro diagnostic manufacturers typically trade at 10x to 18x EBITDA, with companies holding large installed instrument bases commanding premium multiples due to recurring reagent revenue streams. Per U.S. Census Bureau[5] data, the razor-and-blade model creates predictable cash flows valued highly by strategic and financial acquirers.
What SBA loan options are available for diagnostic manufacturing businesses?
The SBA[11] sets the small business threshold at 1,250 employees for NAICS 325413. SBA financing supports smaller specialty reagent producers and point-of-care test kit manufacturers, with 7(a) loans for acquisitions and 504 loans for clean room and manufacturing equipment investments.
What FDA requirements affect IVD substance manufacturers?
The FDA[9] regulates in-vitro diagnostic products as medical devices, requiring 510(k) clearance or premarket approval for commercial distribution. Manufacturers must comply with Quality System Regulation requirements, maintain design history files, and submit to periodic FDA facility inspections.
How does the razor-and-blade model affect IVD business valuations?
Diagnostic instrument placement generates multi-year reagent supply contracts with predictable recurring revenue, creating high-quality cash flow streams. Per the FDA[9], closed-platform systems that require proprietary reagents create strong customer retention and pricing stability valued at premium multiples.
What are the growth drivers for in-vitro diagnostic manufacturing?
Molecular diagnostics, point-of-care testing expansion, companion diagnostics for precision medicine, and laboratory automation drive industry growth. Per the Centers for Medicare and Medicaid Services[14], clinical laboratory testing volumes continue growing with aging demographics and expanded screening guidelines.
How does reimbursement policy affect IVD manufacturers?
Clinical Laboratory Fee Schedule rates set by the Centers for Medicare and Medicaid Services[14] under PAMA directly affect laboratory spending budgets for diagnostic reagents. Reimbursement rate reductions create pricing pressure that flows through to reagent manufacturers from their laboratory customers.
What workforce challenges do IVD manufacturers face?
The Bureau of Labor Statistics[7] reports strong demand for formulation scientists, immunoassay development specialists, and quality systems professionals across the diagnostic manufacturing sector. Competition from pharmaceutical and biotechnology companies for trained scientists creates persistent recruitment challenges.
How has molecular diagnostics changed the IVD industry?
PCR-based and next-generation sequencing diagnostic products represent the fastest-growing IVD segment, driven by oncology, infectious disease, and pharmacogenomic testing demand. Per the FDA[9], emergency use authorizations during the pandemic accelerated molecular diagnostic platform adoption that continues supporting reagent manufacturing growth.
Sources & References
Government datasets and editorial sources used in this report.
- [1]U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages bls.gov
- [2]U.S. Census Bureau, Economic Census census.gov
- [3]U.S. Census Bureau, County Business Patterns census.gov
- [4]U.S. Small Business Administration, SBA 7(a) Loan Program Data data.sba.gov
- [5]U.S. Census Bureau census.gov
- [6]International Trade Administration trade.gov
- [7]Bureau of Labor Statistics bls.gov
- [8]SBA Office of Advocacy advocacy.sba.gov
- [9]FDA fda.gov
- [10]Bureau of Labor Statistics bls.gov
- [11]SBA size standards sba.gov
- [12]SBA 7(a) loan program sba.gov
- [13]CDC/504 loan program sba.gov
- [14]Centers for Medicare and Medicaid Services cms.gov
Disclaimer
This publication has been prepared by Fair Market Value (“Fair Market Value”) for informational purposes only. It is provided on an “as-is” and “as available” basis. Fair Market Value makes no representations or warranties, express or implied, regarding the merchantability, fitness for a particular purpose, completeness, or accuracy of the data or information contained herein. This publication is not intended to be, and should not be construed as, professional financial, legal, tax, or investment advice. Users should consult with qualified professionals before making any financial or business decisions based on the information presented.
To the extent permitted by law, Fair Market Value disclaims all liability for loss or damage, direct and indirect, suffered or incurred by any person resulting from the use of, or reliance upon, the data in this publication.
Copyright © 2026 Fair Market Value. All rights reserved. All data, information, articles, graphs, and content contained in this publication are copyrighted works and Fair Market Value hereby reserves all rights. No part of this publication may be copied, reproduced, republished, uploaded to a third party, or distributed without the prior written permission of Fair Market Value.